INR Target for Rheumatic Heart Disease with Atrial Fibrillation
For patients with rheumatic heart disease and atrial fibrillation, the target INR should be 2.5 (range 2.0-3.0).
Primary Recommendation
The American College of Chest Physicians (ACCP) 2012 guidelines provide the most direct and highest-quality evidence for this specific clinical scenario. For patients with rheumatic mitral valve disease complicated by atrial fibrillation, vitamin K antagonist (VKA) therapy with a target INR of 2.5 (range 2.0-3.0) is strongly recommended over no VKA therapy (Grade 1A) 1. This recommendation applies whether the atrial fibrillation occurs alone or in combination with previous systemic embolism.
Multiple other major guidelines consistently support this same target range:
- The 2006 and 2011 ACC/AHA/ESC guidelines recommend oral anticoagulation with INR 2.0-3.0 for rheumatic heart disease (mitral stenosis) with atrial fibrillation 2, 3
- The American Geriatrics Society guidelines recommend INR target 2.5 (range 2.0-3.0) for rheumatic mitral valve disease with atrial fibrillation 4
Key Clinical Context
Why This Target Range?
The INR range of 2.0-3.0 represents the optimal balance between:
- Thromboembolism prevention: Risk increases substantially when INR falls below 2.0, particularly below 1.8 5
- Bleeding risk: Major bleeding, especially intracranial hemorrhage, increases markedly when INR exceeds 3.5 5
Recent observational data from patients with EHRA type 2 valvular heart disease (which includes rheumatic disease) and atrial fibrillation found that INR 2.0-2.49 was associated with the lowest combined incidence of thromboembolic and bleeding events 6. This supports targeting the lower end of the 2.0-3.0 range.
Important Distinctions
Do not confuse this with higher INR targets used in other scenarios:
- If the patient has a left atrial thrombus documented on TEE (not just atrial fibrillation), a higher target INR of 3.0 (range 2.5-3.5) is recommended 1
- If the patient has recurrent systemic embolism despite adequate anticoagulation, consider escalating to INR target 3.0 (range 2.5-3.5) or adding aspirin 80-100 mg/day 4
Critical Pitfalls to Avoid
Do not use lower INR targets: Some East Asian studies have explored INR ranges of 1.5-2.0, but meta-analysis shows this significantly increases thromboembolism risk (RR 1.50) despite reducing bleeding 7. The standard 2.0-3.0 range should remain the target.
Do not withhold anticoagulation based on AF pattern: Whether the atrial fibrillation is paroxysmal, persistent, or permanent does not change the indication for anticoagulation 8, 9
Do not substitute antiplatelet therapy: Aspirin alone is inadequate for stroke prevention in this population and should not be used as an alternative to warfarin 8, 9
Monitor INR frequently: In resource-limited settings where rheumatic heart disease is prevalent, poor INR control is common with only 27% of measurements in therapeutic range 10. Weekly monitoring during initiation, then monthly when stable, is essential 8
DOACs Are Not Recommended
Direct oral anticoagulants (DOACs) are contraindicated in moderate-to-severe mitral stenosis, which is the most common manifestation of rheumatic heart disease 8, 9. Warfarin remains the only evidence-based anticoagulant for this population. Recent real-world data from Central Australia showed no advantage of DOACs over warfarin in rheumatic heart disease with atrial fibrillation, though this was a small study 11.
Monitoring Strategy
- Target INR: 2.5
- Acceptable range: 2.0-3.0
- Check INR at least weekly during warfarin initiation
- Once stable, check monthly (or more frequently if TTR <70%)
- Aim for time in therapeutic range (TTR) >60-70% for optimal outcomes